SPEX - Biotech vor charttechn. Turnaroundstory?

Ticker: SPEX
Preis: $1.07
http://www.dailyfinance.com/quote/nasdaq/...x-inc/spex/key-statistics
http://www.insidercow.com/history/....jsp?company=spex&B1=Search!
Charts:




 

SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease

PR Newswire Posted 9:15 AM 03/07/12

BETHESDA, Md., March 7, 2012 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today announced that one of its drug candidates, SPX-106T, arrested development and reduced atherosclerotic plaque area in the aortic arch, thoracic aorta and sinus of Valsalva in mice genetically predisposed to cardiovascular disease. Atherosclerosis can lead to myocardial infarction (MI) and stroke. Each year, about 770,000 people in the United States experience their first MI, and about one-third of these events are fatal.(1-3)

(Photo:  http://photos.prnewswire.com/prnh/20120307/PH65219 )

Two groups of apolipoprotein E-deficient mice (control and SPX-106T) were each fed a Western diet (high in fat and carbohydrates) for eight weeks. In the SPX-106T group, the sucrose portion of the dietary carbohydrates was replaced with D-tagatose and SPX-106 was added at 0.1%. Plaque area was quantified at three locations: the sinus of Valsalva on top of the heart, aortic arch, and thoracic aorta (Figure 1a). SPX-106T reduced atherosclerotic plaque areas almost 5-fold in all locations (p<0.05 in thoracic aorta, p≤0.01 in aortic arch and sinus of Valsalva). Photomicrographs of the sinus of Valsalva illustrate the reduction of atherosclerosis with SPX-106T (Figure 1b).

These results expand on previous work done by Spherix, which was presented at the American Association of Pharmaceutical Scientists (AAPS) 2011 national meeting in October, showing that SPX-106T significantly reduced serum cholesterol, the amount of subcutaneous, retroperitoneal, and epididymal body fat, and prevented body weight gain. These data also support Spherix's other findings that SPX-106T reduced atherosclerotic lesion areas in the aortic arches of LDL receptor-deficient mice fed fructose and glucose.

"As we continue the development program for SPX-106T, we are gaining valuable insight into the therapeutic potential for SPX-106T. We are looking forward to bringing SPX-106T into human clinical trials in 2012," noted Dr. Claire Kruger, CEO of Spherix.

LDL-cholesterol is a known risk factor for the development of atherosclerosis in humans.(4) Spherix has previously shown that LDL-cholesterol is reduced in LDL receptor-deficient mice treated with SPX-106T.

"This is a very exciting time for Spherix," remarked Dr. Robert Lodder, Spherix's President. "We have now tested SPX-106T in two different genetic models and are looking into the underlying mechanisms by which SPX-106T prevents plaque development in the apolipoprotein E-deficient mice. We are also expanding the applications of SPX-106T to other indications where dyslipidemia may be a primary risk factor."

About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis.  Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke.  Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934.  Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of our products, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop products may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission.  Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

   NHLBI, http://www.nhlbi.nih.gov/health/health-topics/topics/heartattack/
   WHO, http://www.who.int/mediacentre/factsheets/fs310.pdf
   Genentech, http://www.gene.com/gene/products/education/...tattack-factsheet.html
   Cleeman, J.I. (2002). Executive Summary of the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).

SOURCE Spherix Incorporated

http://www.dailyfinance.com/rtn/pr/...sease/rfid539436998/?channel=pf  

SPEX,
O/S 4,167,820 verified by me with the Transfer Agent this afternoon.
American Stock Transfer and Trust Company

Operations Center
6201 15th Avenue
Brooklyn, NY, 11219
800-937-5449
http://www.amstock.com
It dawned on kajulie and I that this company is trading well below it's cash value alone which is why i called the T/A and then the company. Got a call back not long ago from an adviser to the company who verified the O/S and cash. The shares are a bit higher than listed on Yahoo finance as a result of an offering that opened on 2 Feb and closed on 7 Feb.
Spherix has issued an aggregate of 1,064,815 shares of common stock at a price of $1.08 per share along with warrants to purchase an additional 212,963 shares of common stock at an exercise price of $1.40 per share.
With $5.02 million in cash and the O/S would value the companies share price at approx $1.2044/share and closed today at .82 and that's with just the cash and no news/assets or about .40/share and that's a nice gain. Nothing else. Chart is shaping up as well. As for volume, well this Biotech hasn't been noticed yet. ioo it's one of those rare diamonds you don't find every day. Best to all..

http://investorshub.advfn.com/boards/...id=72903826&txt2find=spex  

March 12, 2012

Dr. Robert Lodder, President, will be presenting a paper at PittCon 2012 in the Orlando Convention Center, Orlando, FL.  The title is "Molecular Factor Computing (MFC) of the Extent of Atherosclerosis in D-Tagatose Treatment," in room 308D at 3:35 PM.
March 15, 2012

Dr. Robert Lodder, President, will be presenting a paper at PittCon 2012 in the Orlando Convention Center, Orlando, FL.  The title is "Measurement of Lipoproteins in Treatment with SPX-106," in room 308C at 10:15 AM.

http://www.biospherics.com/investors_events.html  

http://execvid.com/spherix-incorporated-v1  

von dir..muß das mal so off topic schreiben da es mit den sternen  bei dir nicht mehr geht.  

 This morning, North South Holdings, a company that Spherix is purchasing, announced that it filed a patent infringement suit against T-Mobile USA (NYSE: TMUS) claiming that it infringed on a patent entitled, “System and Method for Determining the Geolocation of a Transmitter.” According to the release, The technology relates to the geolocation of cell phones on the T-Mobile cell phone network.

http://breakingfinancenews.com/headlines/...percent-monday-spex/2311/

 

vielleicht ist schon was durchgesickert, was die patente angeht

http://seekingalpha.com/article/...on-patent-monetization?source=feed

rt:

http://www.nasdaq.com/symbol/spex/real-time

vom 09.04.2014


http://seekingalpha.com/article/...nt-monetization?source=feedSummary

•Spherix is a $71 million company owning over 300 patents that could turn into billions of dollars through litigation, licensing or outright sale.
•Spherix's reverse merger resulted in a complex share structure that nevertheless incentivizes institutional backers toward higher share prices.
•Spherix's lawyer-turned-CEO Anthony Hayes rewarded all shareholders with a 5x cash return on his most recent public company project.
Spherix (SPEX) is a low float Nasdaq stock that turns intellectual property ("IP") into money through selling, litigating and/or licensing these intangible assets. The company is led by a lawyer who rewarded Mango Capital shareholders with a 5x cash return by monetizing an obscure patent portfolio. Boasting over 90% insider and institutional ownership, Spherix is backed by some of the most successful IP investors in the world, including Apple (AAPL), and has five active lawsuits: one major lawsuit against Cisco (CSCO) and four others against Uniden, AT&T (T), VTech (OTCPK:VTKLY) and T-Mobile (TMUS). As Spherix pursues its aggressive strategy, I wanted to update my research on this young company.

Already a Record-Setting Year for IP
Spherix has enjoyed rapid growth along with the overall IP monetization sector. As PricewaterhouseCoopers predicted, 2014 is already breaking all-time records. Patent lawsuit filings increased by over 30% during the past 12 months, and courts are awarding the largest patent infringement damages ever.

über 2 dollar brennt der baum.ziel wäre dann 4-5 dollar.(: )  

heutigen afterhour-kauf von 435.000 stücken auf einen schlag

da hatte es aber einer eilig sich einzudecken.sehr gespannt was morgen geht.  

jmnd die letzten Quartalszahlen gelesen? Liest sich m.E. zum Teil nicht so schön.....  

die bodenbildung.untermauert wird das ganze durch den volumenchart.an den fetten grünen balken sieht man das vermehrt käufer auftreten.ich denke die zeit ist reif.aktuelle MK 15 mio dollar.patente stehen mit rund 70 mio in den büchern laut einem WO experten.(: ) es gibt keine schulden.denke hier fehlt nur noch eine news wo die spekulation der breiten masse näher gebracht wird dann gibts kein halten mehr.  

Ist aber eine sehr spekulative Kiste. So viel cash ist nämlich nicht mehr vorhanden. Sofern nicht bald ein Patent bzw eine Klage Geld bringt können auch schnell die Lichter ausgehen.....  

 

uschiw @prooblem ist dann auch bald pleite*lach*  

Die Rakete zündet :-)

http://www.sharedeals.de/2014/05/26/...gruende-fuer-1-000/#more-15445  

.......die neue Santhera?  

...steigt weiter....